Oppenheimer downgraded Vertex Pharmaceuticals (VRTX) to Perform from Outperform without a price target after the company announced results from its Phase 2 study of suzetrigine in people with painful ...

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced results from its Phase 2 study of suzetrigine, an investigational, oral, highly selective NaV1.8 pain signal ...

PALM SPRINGS, California — A new sodium channel blocker, CNV1014802, reduces neuropathic pain from lumbosacral radiculopathy, a phase 2 trial shows. Patients taking the drug improved by about 1 point ...

The lumbosacral plexus is formed by the ventral branches of the second to fifth lumbar nerves. The lower division of the fourth lumbar nerve joins the fifth, and the lumbosacral trunk thus formed ...

A former Senior Publishing Editor on the Dow Jones Newswires team at The Wall Street Journal, Aaron earned a Bachelor's degree in Economics from the University of Michigan and a Master's in Journalism ...

Please provide your email address to receive an email when new articles are posted on . Sacral fractures occur in approximately 45% of pelvic fractures. An associated neurologic injury of the ...

Having one drug on the market is generally not enough to keep a biotech or its investors happy. That's especially true for Zalicus (NAS: ZLCS) , which out-licensed its pain drug Exalgo to Covidien ...

– Treatment with the highly selective NaV1.8 pain signal inhibitor suzetrigine met the primary endpoint with a statistically significant and clinically meaningful 2.02 point within-group reduction ...